Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Equity Ratio (2020 - 2025)

Lyell Immunopharma's Equity Ratio history spans 6 years, with the latest figure at 0.78 for Q2 2025.

  • For Q2 2025, Equity Ratio fell 10.45% year-over-year to 0.78; the TTM value through Jun 2025 reached 0.78, down 10.45%, while the annual FY2024 figure was 0.78, 10.69% down from the prior year.
  • Equity Ratio for Q2 2025 was 0.78 at Lyell Immunopharma, down from 0.78 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.89 in Q1 2023 and bottomed at 0.78 in Q2 2025.
  • The 5-year median for Equity Ratio is 0.85 (2022), against an average of 0.84.
  • The largest annual shift saw Equity Ratio surged 356.07% in 2021 before it dropped 10.69% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.82 in 2021, then increased by 7.76% to 0.89 in 2022, then fell by 1.75% to 0.87 in 2023, then fell by 10.69% to 0.78 in 2024, then fell by 0.56% to 0.78 in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Equity Ratio are 0.78 (Q2 2025), 0.78 (Q1 2025), and 0.78 (Q4 2024).